Search
forLearn
5 / 801 resultslearn TDM-105795
learn RH410
learn KX-826
learn Selenium AAC
Research
5 / 1000+ resultsresearch Total glucosides of paeony inhibit NLRP3/caspase-1/GSDMD-mediated inflammation and pyroptosis in C3H/HeJ mice with alopecia areata
Total glucosides of paeony may help treat alopecia areata by reducing inflammation and hair loss.
research Advancements in research on the immune-inflammatory mechanisms mediated by NLRP3 inflammasome in ischemic stroke and the regulatory role of natural plant products
Natural plant products like Proanthocyanidins and curcumin may help treat ischemic stroke by reducing inflammation.
research Application of metal organic frameworks-based functional composite scaffolds in tissue engineering
Metal organic frameworks-based scaffolds show promise for tissue repair due to their unique properties.
research Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
New therapies and trials are needed for Merkel cell carcinoma, a tough skin cancer.
research 578 Addressing the missing components for appropriate surveillance of Merkel cell carcinoma patients: Detailed recurrence data and an integrated risk analysis approach
Merkel cell carcinoma is most likely to recur within two years of diagnosis, and factors like immune suppression, being over 75, and male sex increase this risk.
Community Join
5 / 1000+ resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community hmi115 is coming. Prepare yourselves for what's coming
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
community Did anyone get their KX-826 from Koshinemall yet?
The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.